Medpace Holdings, Inc. (MEDP)
POSITIVEFundamental
69
मूल्य
$618.73
मार्केट कैप
$17.31B
भाग 1 · कंपनी का मूल्य कितना है
अवलोकन
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
बैलेंस शीट और तरलता
राजस्व
$2.78B
पिछले 12 महीने (30/6/2026 तक)
शुद्ध आय
$492M
पिछले 12 महीने (30/6/2026 तक)
Free Cash Flow
$682M
कुल इक्विटी
$459M
कुल देनदारियाँ
$1.52B
Current Ratio
0.73
Interest Coverage
-
Debt/EBITDA
0.24
Earnings Per Share
राजस्व और शुद्ध आय
Free Cash Flow
आय विवरण
ऐतिहासिक विवरण
समय के साथ मार्जिन
समय के साथ ऋण
ऋण कितना भारी है
वृद्धि तालिका
वृद्धि — राजस्व
Fair Value अनुमान
Fair Value
$847.98
वर्तमान मूल्य
$618.73
Margin of Safety
+27.0%
Fair Value सीमा
$551.19 - $1144.77
अनुमान विधियाँ
मूल्यांकन मेट्रिक्स
P/E Ratio
36.39
ROE
98.3%
P/B Ratio
39.89
P/FCF
24.49
Gross Margin
-
ROIC
74.1%
लाभप्रदता Radar
Value Creation (Economic Moat)
ROIC
74.1%
WACC
10.9%
ROIC − WACC
+63.2 pp
ROIC exceeds the cost of capital — the company is creating value for shareholders.
Fundamental विश्लेषण मानदंड
पास (17)
- EPS shows upward trend
- Price CAGR 32.92%
- ROIC 74.1%
- P/FCF 24.49
- Debt/Equity ratio
- Operating Margin 21.0%
- Positive Free Cash Flow
- CapEx intensity
- Debt/EBITDA
- Return on Tangible Assets
- ROE 110.1%
- Revenue Growth 5Y 22.3%
- Earnings Surprise avg 7.5%
- PEG Ratio 1.05
- Earnings Quality (OCF/NI) 1.53
- Share Dilution -7.8%
- Piotroski F-Score 6/9
फेल (7)
- P/B Ratio 39.89
- Current Ratio
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- Analyst Consensus 35% Buy
- Net Margin Trend 17.7% vs 18.7%
अनुपलब्ध (3)
- Gross Margin NaN%
- Dividend Payout NaN%
- Interest Coverage
Piotroski F-Score
मिश्रित संकेत: कुछ क्षेत्रों पर ध्यान देना आवश्यक
Earnings गुणवत्ता
उच्च गुणवत्ता: earnings नकदी द्वारा समर्थित
शेयर Dilution
शेयर वापस खरीद रही है। शेयरधारक अनुकूल
प्रशासन
कार्यकारी टीम
| नाम | पद | आयु |
|---|---|---|
| Dr. August James Troendle M.D. | CEO, President & Chairman | 69 |
| Mr. Kevin M. Brady | CFO & Treasurer | 50 |
| Mr. Stephen P. Ewald J.D. | Chief Compliance Officer, General Counsel & Corporate Secretary | 56 |
| Mr. Brad W. Hansman | Executive Vice President of Operations | 42 |
| Ms. Lauren Morris | Associate Director of Investors Relations | - |
| Mr. Todd Meyers | Vice President of Business Development & Marketing | - |
| Mr. Weimin Gai MS | Senior Vice President of Biometrics | - |
| Mr. John T. Wynne MBA | Chief Business Officer | - |
| Ms. Reinilde Heyrman M.D. | Chief Medical Officer of Medical Department | 64 |
| Ms. Gina Leisring M.P.H. | Senior Vice President of Clinical Monitoring | - |
Audit जोखिम
6
बोर्ड जोखिम
8
मुआवजा जोखिम
4
शेयरधारक अधिकार जोखिम
5
भाग 2 · कीमत और खरीदने का समय
यह हिस्सा यह नहीं बताता कि कंपनी अच्छी है या नहीं: यह तय करने में मदद करता है कि उसे कब खरीदें, जब फंडामेंटल आपको आश्वस्त कर चुके हों। इसमें: तकनीकी विश्लेषण, संभावना, ऐतिहासिक गिरावट, गामा एक्सपोज़र।
Latest News
Recent headlines for MEDP, sourced from Markets Gazette.